Key Statistics

Key statistics for the anti-infectives market can be summarised as follows:

• ca 85 % of the current antibiotic clinical pipeline is for the treatment of Gram positive infections
• A lean pipeline of new drugs targeting problems of hospital and community acquired Gram negatives exists
• 2 million nosocomial infections in the US per annum - problem pathogens include MRSA, VRE (Endocarditis)
  and Gram negatives
• Community based infections are increasing with a market of $ 17 - 18 billion (problem pathogen
  Streptococci & Klebsiella)
• Treatment of hospital infections is usually by intravenous administration costing $ 6.7 Bn in 2005

Against this backdrop it is Sealife’s intention is to focus on developing new first in class small molecule compounds based on the novelty of marine fungal chemical diversity against Gram negative and Gram positive organisms, with the problem pathogens considered to be Enterococci, MRSA, Pseudomonas, Acinetobacter, Klebsiella, Streptococci & Staphylococci.